Updates on therapy for medullary thyroid cancer in 2021
- PMID: 34921811
- DOI: 10.1016/j.ando.2021.12.002
Updates on therapy for medullary thyroid cancer in 2021
Abstract
Medullary thyroid cancer (MTC) is a rare form of thyroid cancer, frequently linked to a germline or somatic mutation in the RET proto-oncogene. MTC has a good prognosis at the localized stage but prognosis is worse in case of metastases, although there is considerable heterogeneity in progression even in advanced stages. Classical chemotherapy shows little efficacy in this type of cancer. Over the last decade, new effective anti-cancer therapies, in particular multi-targeted tyrosine kinase inhibitors and selective anti-RET tyrosine kinase inhibitors, have changed the management of patients with advanced MTC. The aim of this review is to report the results of studies of these new treatments, and to update the state of knowledge from ongoing studies of treatments such as vectorized internal radiotherapy. In chronic forms, which are incurable but with slow progression, the development of new lines of treatment that can reduce the phenomena of acquired resistance is a major issue.
Keywords: Cancer médullaire de la thyroïde; Cancers de la thyroïde; Medullary thyroid cancer; Multiple endocrine neoplasia; Néoplasies endocriniennes multiples; Thyroid cancer.
Copyright © 2021. Published by Elsevier Masson SAS.
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Medical